I-FDA-evunyelwe i-Hepatitis C Izidakamizwa

Imithi ehlinzeka ngamazinga okuphulukisa amazinga angaphezulu kwamaphesenti angu-99

Ngesikhathi umuthi weSovaldi (sofosbuvir) uqala ukuqala ngoSeptemba 2014, awuzange nje umake ushintsho olwandle ngendlela ukutheleleka kwe-hepatitis C okwelashwa ngayo, okwenza imishanguzo yezizukulwane zangaphambilini ezingasasebenzi ezazingekho eduze. Ezinyangeni ezingakapheli ukufika kukaSovaldi, lesi sifo esibizwa ngokuthi i-Incivek (telaprevir) no-Victrelis (boceprevir) sasiqala ngokushesha emakethe, singasabonakali futhi.

Ukulandela okusheshayo ezithendeni zikaSovaldi kwakungeniswa kwezimbangela eziyisithupha zokudakwa kwezidakamizwa ezikwazi ukuphatha uhla olubanzi lwezinhlobo ze-hepatitis C. Lezi zidakamizwa ezintsha zanikeza nje imiphumela emibi kakhulu, zanciphisa inkambo yokwelapha cishe izinyanga ezintathu.

Ngamazinga okuphulukisa manje angaphezu kwamaphesenti angu-95 ezimweni eziningi, inselelo yodwa kuphela yindlela yokwandisa ukufinyelela kubantu abayizigidi ezingu-130 kuya kwezigidi ezingu-150 abantu abanesandulela ngculazi emhlabeni jikelele.

Nazi izindlela ezintsha eziyisishiyagalombili zokunakekelwa kwe-hepatitis C, ezibalwe ngokomyalelo wokugunyazwa kwabo kwe-FDA:

1 -

I-Epclusa

Kuvunyelwe ngoJuni 28, 2016, i-Epclusa (i-sofosbuvir, i-velpatasvir) iyithebhulethi yezinhlanganisela ezimbili noyedwa ekwazi ukuphatha zonke izinhlobo zesithupha ze-hepatitis C ezinkulu. Ingasetshenziselwa ukuphatha abantu abane-cirrhosis (kufaka phakathi i- cirrhosis ekhokhelwayo ). I-Epclusa inqunywe ngomthamo owodwa wansuku zonke isikhathi semasonto ayisithupha.

Okuningi

2 -

I-Zepatier

Kuvunyelwe ngoJanuwari 2016, i-Zepatier (elbasvir, i-grazoprevir) iyinhlanganisela ye-dose ehlanganisiwe yokusebenzisa ama-genotypes 1 no-4 noma ngaphandle kwe-cirrhosis. I-Zepatier iyindlela yokwelashwa eyodwa-eyodwa engadingi ukuphathwa nanoma imuphi omunye umuthi. Kuthathwa kanye nsuku zonke noma ngaphandle kokudla amasonto angu-12 kuya kwangu-16, kuye ngokuthi uhlobo lomuntu obenalo yini futhi ngabe umuntu lona uphethwe ngaphambili yini nge-hepatitis C.

Okuningi

3 -

I-Daklinza

Kuvunyelwe ngoJulayi 2015, iDadlinza (daclatasvir) isetshenziselwa ukwelashwa okuhlanganyelwe ukwelapha isifo sofuba se-hepatitis C. I-Daklinza yi-anti-antiviral yokuqala yokusebenza ngokuqondile ekwazi ukuphatha i-genotype 3 ngaphandle kokungezwa kwe- peginterferon noma i- ribavirin . I-Daklinza ithathwa kanye noSovaldi kanye nsuku zonke noma ngaphandle kokudla okwesikhathi samasonto angu-12.

Okuningi

4 -

I-Technivie

Kuvunyelwe ngoJulayi 2015, i-Technivie (i-ombitasvir, i-paritaprevir / ritonavir) iyisidakamizwa esisetshenziselwa ukwelashwa okuhlangene ukuphatha abantu abane-infection ye-genotype 4. Lezi zinxusa zezidakamizwa ezibandakanya i-Technivie zifakwe esikhungweni sepilisi ezimbili, i- Viekira Pak . Isilinganiso esinconywayo amaphilisi amabili athathwa kabili nsuku zonke nge ribavirin amasonto angu-12.

Okuningi

5 -

Viekira Pak

Ukwamukelwa ngoDisemba 2014, i-Viekira Pak iyindlela yokwelashwa ehlanganisiwe esetshenziselwa ukwelapha isifo sofuba se-hepatitis C noma ngaphandle kwe-cirrhosis. Iphakethe lihlanganisa i-Technivie yezidakamizwa ezihlanganisiwe eceleni kwesidakamizwa esengeziwe esibizwa ngokuthi i-dasabuvir. Izinga eliphakanyisiwe yiziphilisi ezimbili zeTechnvie ezithathwe kanye nsuku zonke ngokudla kanye ne-tablet eyodwa yedasabuvir ethathwe kabili nsuku zonke ngokudla. Isikhathi sokwelapha sisuka emavikini angu-12 kuya kwangu-24.

Okuningi

6 -

Harvoni

Kuvunyelwe ngo-Okthoba 2014, i-Harvoni (ledipasvir, sofosbuvir) iyinhlanganisela ye-dose fixed-dose esetshenziselwa ukuphatha izifo ze-genotypes 1 no-4 noma ngaphandle kwe-cirrhosis. Ingasetshenziswa futhi kwezinye izimo ze-genotype 3. I-Harvoni yayiyindlela yokuqala yokwenza izidakamizwa ezokuqala, okungazange idinge ukusebenzisana nge-peginterferon noma i-ribavirin. Izinga eliphakanyisiwe liyi-tablet eyodwa nsuku zonke ethathwe noma ngaphandle kokudla. Isikhathi sokwelapha sisuka emavikini angu-12 kuya kwangu-24.

Okuningi

7 -

I-Sovaldi

Ukwamukelwa ngoDisemba 2013, iSovaldi (sofosbuvir) iyinveli yomuthi we-antiviral esetshenziswa ngokuqondile ukusetshenziselwa ukuphatha i-genotype 1, 2, 3 no-4. Izinga eliphakanyisiwe lilodwa ithebulethi nsuku zonke ezithathwe noma ngaphandle kokudla. Kuye nge-genotype, i-ribavirin ingase ifakwe emthwalweni. Ngokutheleleka kwe-genotypes 3, uSovaldi ulawulwa ngokuhambisana neDadlinza. Isikhathi sokwelapha sisuka emavikini angu-12 kuya kwangu-24.

Okuningi

8 -

I-Olysio

Kuvunyelwe ngoNovemba 2013, i-Olysio (simeprevir) yisidakamizwa se-protease inhibitor-class esetshenziselwa ukwelashwa okuhlanganyelwe ukuphatha abantu abane-infection ye-hepatitis C yesandulela-1. I-Olysio isetshenziselwa ukuhlanganiswa kokubili i-peginterferon ne-ribavirin isikhathi semasonto angu-24 kuya kwangu-36. Izinga eliphakanyisiwe lithebulethi eyodwa ethathwa nsuku zonke ngokudla.

Okuningi